Table 5.

Associations between ET-only and EPT Use and Lung Cancer Risk by Histology, NIH-AARP Diet and Health Study Cohort

				Non-Small Cell Carcinomas
	Small Cell (n= 357)			Adenocarcinoma (n= 928)			Squamous Cell (n= 279)			Non-small cell, NOS (n= 248)			Undifferentiated/ Large cell (n= 109)
Hormone Therapy	RR	95% CI		RR	95% CI		RR	95% CI		RR	95% CI		RR	95% CI
ET only use - All women
No	1.00	reference		1.00	reference		1.00	reference		1.00	reference		1.00	reference
Yes	0.97	0.73	1.29	0.90	0.75	1.08	0.88	0.64	1.22	1.09	0.77	1.53	1.50	0.90	2.50
Recency of use
Former	0.91	0.62	1.35	0.91	0.71	1.17	0.80	0.52	1.25	1.13	0.72	1.77	1.66	0.89	3.09
Current	1.02	0.74	1.41	0.90	0.73	1.10	0.89	0.61	1.28	1.09	0.74	1.63	1.46	0.81	2.62
Duration of use (y)
<5	1.09	0.76	1.55	0.83	0.64	1.07	1.04	0.70	1.55	1.17	0.75	1.81	1.14	0.56	2.32
5–9	1.19	0.71	1.98	0.88	0.62	1.26	0.95	0.51	1.75	0.99	0.49	1.99	1.19	0.41	3.45
≥10	0.83	0.57	1.20	0.96	0.77	1.19	0.71	0.47	1.08	1.08	0.70	1.67	1.96	1.07	3.60
				Non-Small Cell Carcinomas
	Small Cell (n= 203)			Adenocarcinoma (n= 500)			Squamous Cell (n= 157)			Non-small cell, NOS (n= 147)			Undifferentiated/ Large cell (n= 58)
Hormone Therapy	RR	95% CI		RR	95% CI		RR	95% CI		RR	95% CI		RR	95% CI
EPT use - Women with intact uteri
No	1.00	reference		1.00	reference		1.00	reference		1.00	reference		1.00	reference
Yes	0.91	0.66	1.25	1.05	0.86	1.28	0.88	0.60	1.27	1.26	0.87	1.83	1.19	0.66	2.16
Recency of Use
Former	0.99	0.58	1.67	1.27	0.94	1.72	1.05	0.59	1.88	1.26	0.70	2.29	1.87	0.85	4.14
Current	0.90	0.63	1.29	0.97	0.78	1.21	0.81	0.52	1.24	1.29	0.86	1.94	0.88	0.43	1.82
Duration of use (y)
<5	0.88	0.56	1.39	1.10	0.84	1.42	0.83	0.49	1.42	1.56	0.98	2.47	1.45	0.69	3.05
5–9	0.85	0.49	1.46	0.82	0.58	1.16	0.69	0.34	1.38	1.03	0.54	1.96	0.87	0.30	2.53
≥10	0.97	0.59	1.59	1.19	0.89	1.59	1.12	0.66	1.90	1.18	0.66	2.10	1.24	0.50	3.05

RR adjusted for age, race, age at menarche, menopausal type and age, BMI, emphysema diagnosis, cigarette status and number of cigarettes/day, and other hormone therapy formulations.